Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9065MR)

This product GTTS-WQ9065MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9065MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6313MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ15221MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ675MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ5612MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ15299MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ12178MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ3989MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ11770MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-1308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW